login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
JANUX THERAPEUTICS INC (JANX) Stock News
NASDAQ:JANX -
US47103J1051
-
Common Stock
23.29
USD
+0.25 (+1.09%)
Last: 9/4/2025, 1:24:38 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
JANX Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: The Motley Fool
Janux (JANX) R&D Soars Revenue Misses
a month ago - By: Janux Therapeutics
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
a month ago - By: Janux Therapeutics
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
a month ago - By: Janux Therapeutics
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
2 months ago - By: Janux Therapeutics
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
2 months ago - By: Benzinga
- Mentions:
TEVA
EW
LLY
NVO
...
10 Health Care Stocks Whale Activity In Today's Session
9 months ago - By: Benzinga
Navigating 10 Analyst Ratings For Janux Therapeutics
4 months ago - By: Janux Therapeutics
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
4 months ago - By: Janux Therapeutics
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
4 months ago - By: Yahoo Finance
Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential
9 months ago - By: The Motley Fool
Why Janux Therapeutics Crushed the Market Today
4 months ago - By: Yahoo Finance
- Mentions:
GEHC
IDYA
BCYC
CNTA
...
Here's Why GE HealthCare Stock Sank in April
4 months ago - By: Janux Therapeutics
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
4 months ago - By: Yahoo Finance
- Mentions:
SKX
COGT
EWTX
BCYC
...
State Street Report Shows Big Slump in April ETF Inflows
4 months ago - By: Yahoo Finance
- Mentions:
DHI
CMG
Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
4 months ago - By: Yahoo Finance
- Mentions:
EVTL
BCYC
EWTX
IDYA
...
Is Vertical Aerospace Ltd. (EVTL) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
4 months ago - By: Yahoo Finance
- Mentions:
AMD
BCYC
REXR
Chart of the Week: '10x Money Multiplier' for Bitcoin Could Take Wall Street by Storm
5 months ago - By: Yahoo Finance
- Mentions:
OKTA
CORW
ANET
AVGO
...
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?
6 months ago - By: Janux Therapeutics
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
9 months ago - By: Janux Therapeutics
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
9 months ago - By: Janux Therapeutics
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
9 months ago - By: Janux Therapeutics
Janux Therapeutics Announces Proposed Public Offering
9 months ago - By: Investor's Business Daily
- Mentions:
VIR
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
9 months ago - By: Janux Therapeutics
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
Please enable JavaScript to continue using this application.